首页> 外文会议>Progress on post-genome technologies and modern natural products >HIGH THROUGHPUT SEQUENCING OF IMMUNE REPERTOIRE FOR BIOMARKER DISCOVERY
【24h】

HIGH THROUGHPUT SEQUENCING OF IMMUNE REPERTOIRE FOR BIOMARKER DISCOVERY

机译:用于生物标记物发现的免疫目录的高通量排序

获取原文
获取原文并翻译 | 示例

摘要

@@With rapid development of the nextGen sequencing technology, the question is no longer about how to sequence, but what to sequence. We have developed technologies and bioinformatic pipelines that allow us to study immune repertoire with high throughput sequencing. The human immune system produce the most sensitive, early, and specific reaction to any diseases conditions, therefore, sequencing the personalized repertoire will help identify disease specific markers. Early studies of cancer and other diseases identified two significant changes in immune repertoire: (1) reduced repertoire diversity, as measured by the D50 value; and (2) increased sharing of cancer specific T cells with specific CDR3 sequences. Encouraged by the early findings, we have launched a major international collaboration study, the R10K project (www. R10K. org), aimed to sequence 10 000 samples and study 100 different diseases. The aim of the project is to identify disease specific biomarkers for early diagnosis, prognosis, and help with diseases management
机译:@@随着下一代测序技术的快速发展,问题不再是如何测序,而是要测序什么。我们已经开发了技术和生物信息流水线,使我们能够通过高通量测序研究免疫库。人类免疫系统对任何疾病都产生​​最敏感,最早期和最特异性的反应,因此,对个性化库进行测序将有助于鉴定疾病特异性标记。对癌症和其他疾病的早期研究确定了免疫库中的两个重要变化:(1)D50值降低了库的多样性; (2)增加癌症特异性T细胞与特异性CDR3序列的共享。受早期发现的鼓舞,我们启动了一项重要的国际合作研究,即R10K项目(www.R10K.org),旨在对10,000个样本进行测序并研究100种不同的疾病。该项目的目的是识别特定于疾病的生物标志物,以进行早期诊断,预后并帮助疾病管理

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号